Vimy Pharma, a newly established Canadian pharmaceutical company, aims to launch a generic version of Ozempic, a popular drug for diabetes and weight loss, following the expiration of data protection on its active ingredient, semaglutide. With a focus on domestic production amid global supply chain concerns, Vimy is set to file its application with Health Canada soon. If approved, the drug will be manufactured in Edmonton, potentially creating around 30 jobs and responding to the rising demand for affordable medications in Canada.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
